Aclaris Therapeutics Inc (NASDAQ:ACRS) has received an average rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $47.25.

A number of equities research analysts recently weighed in on ACRS shares. BidaskClub upgraded shares of Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 13th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Wednesday, August 8th. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Monday, July 9th. Finally, JMP Securities reduced their price target on shares of Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, October 16th.

In related news, Director Stephen A. Tullman bought 6,250 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were bought at an average price of $15.97 per share, with a total value of $99,812.50. Following the transaction, the director now owns 163,757 shares in the company, valued at $2,615,199.29. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen A. Tullman bought 6,600 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the transaction, the director now owns 170,357 shares in the company, valued at approximately $2,555,355. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 19,950 shares of company stock valued at $298,213. 17.00% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in shares of Aclaris Therapeutics by 31.1% in the 2nd quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock valued at $67,015,000 after acquiring an additional 796,805 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Aclaris Therapeutics by 9.7% in the 2nd quarter. BlackRock Inc. now owns 2,311,641 shares of the biotechnology company’s stock valued at $46,163,000 after purchasing an additional 204,215 shares during the period. Rice Hall James & Associates LLC lifted its stake in shares of Aclaris Therapeutics by 88.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 399,342 shares of the biotechnology company’s stock valued at $7,975,000 after purchasing an additional 187,545 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Aclaris Therapeutics by 3,694.2% in the 1st quarter. JPMorgan Chase & Co. now owns 190,281 shares of the biotechnology company’s stock valued at $3,333,000 after purchasing an additional 185,266 shares during the period. Finally, C WorldWide Group Holding A S lifted its stake in shares of Aclaris Therapeutics by 221.9% in the 2nd quarter. C WorldWide Group Holding A S now owns 242,251 shares of the biotechnology company’s stock valued at $4,838,000 after purchasing an additional 166,986 shares during the period. 99.75% of the stock is currently owned by institutional investors.

ACRS traded up $0.33 on Tuesday, reaching $12.50. 635,682 shares of the company traded hands, compared to its average volume of 402,405. Aclaris Therapeutics has a one year low of $11.00 and a one year high of $27.05.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.04. Aclaris Therapeutics had a negative net margin of 1,584.99% and a negative return on equity of 49.45%. The company had revenue of $3.68 million during the quarter, compared to analyst estimates of $2.76 million. Research analysts forecast that Aclaris Therapeutics will post -5.38 EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Further Reading: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.